Powder: -20°C for 3 years | In solvent: -80°C for 1 year
AVE-3085 is a potent enhancer of endothelial nitric oxide synthase, and used for cardiovascular disease treatment.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
2 mg | 5 days | $ 98.00 | |
50 mg | 6-8 weeks | $ 764.00 | |
100 mg | 6-8 weeks | $ 1,210.00 |
Description | AVE-3085 is a potent enhancer of endothelial nitric oxide synthase, and used for cardiovascular disease treatment. |
In vitro | AVE3085 also prevents the elevation of O2.? and ONOO? levels in coronary arteries exposed to ADMA[2]. AVE3085 (10 μM) markedly increases ACh-induced relaxations in SHR aortae without affecting those in WKY aortae. And it also increases the eNOS expression in WKY aortae[3]. Pre-incubation with AVE3085 restores the bradykinin-induced relaxation, reverses the decrease of p-eNOSSer1177, and loares the level of p-eNOSThr495 and nitrotyrosine. NO release in response to bradykinin is significantly reduced by ADMA and such reduction is restored by AVE3085. |
In vivo | AVE 3085 treatment notably mitigates the rise in Smad2 mRNA expression and reduces collagen volume fraction levels relative to vehicle-treated mice. This treatment, administered over four weeks at 10 mg/kg/day orally, elevates p-eNOS and eNOS protein levels in SHR aortae without affecting those in WKY aortae. Additionally, it effectively hinders increases in left ventricular weight, the left ventricular weight/body weight ratio, mean myocyte diameter, and the expression of hypertrophic markers ANP and β-MHC, compared to vehicle-treated controls. AVE 3085 significantly enhances ACh-induced endothelium-dependent relaxations in SHR aortae and decreases systolic blood pressure in SHRs. Treatment with AVE 3085 also markedly improves cardiac function indicators such as EFs, FSs, mitral E velocity, E/A ratio, and LVDds, alongside significantly upregulating eNOS protein expression, when compared to the AB group treated with a vehicle. |
Synonyms | AVE-3085 |
Molecular Weight | 317.29 |
Formula | C17H13F2NO3 |
CAS No. | 450348-85-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
AVE3085 450348-85-3 Others AVE-3085 AVE 3085 inhibitor inhibit